. Author manuscript; available in PMC: 2011 Sep 1.

Published in final edited form as: Nanomedicine (Lond). 2010 Nov;5(9):1341–1356. doi: 10.2217/nnm.10.87

Table 1.

Vesicle composition, their physicochemical and MR relaxivity properties.

Vesicles	Vesicle composition (mol. % of lipid)^†					Mean size (nm)	PDI	Zeta potential (mV)	r₁at 1.5 T (s⁻¹.mM⁻¹)
Vesicles	PC	PS	9-CCN	Chol	9-CCN-OMe	Mean size (nm)	PDI	Zeta potential (mV)	r₁at 1.5 T (s⁻¹.mM⁻¹)
oxPL	44.8	5.0	15.0	20.0	0.0	130	0.179	−69.95 ± 1.91	5.9 ± 0.1
PL	44.8	5.0	0.0	35.0	0.0	140	0.202	−46.92 ± 2.49	5.7 ± 0.1
mePL	44.8	5.0	0.0	20.0	15.0	112	0.671	−45.21 ± 4.33

^†

All formulations contained 15 mol.% of Gd-DTPA-SA and 0.2 mol.% of rhodamine-DOPE.

mePL: (3b)-cholest-5-en-3-yl methyl azelaate phospholipid vesicles; oxPL: Cholesteryl-9-carboxynonanoate phospholipid vesicles; PC: Phosphatidylcholine; PDI: Polydispersity indices; PL: Phospholipid; PS: Phosphatidylserine.